SEC Form 4Coverage since May 29, 2026
$AUPH insider trading
Over the last 12 months, Aurinia Pharmaceuticals insiders reported 5 buys totaling $12.5M and no sales across SEC Form 4 filings.
- Bought · 12m
- $12.5M 5 events
- Sold · 12m
- — 0 events
- Events · 12m
- 5 Form 4 filings, grouped
- Insiders · 12m
- 1 distinct reporters
- 10b5-1 share
- 0% pre-arranged plans
Side
Price · $AUPH · 12Mvia TradingView
Top insiders · 12m
TANG KEVINChief Executive Officer5× · $12.5M
All insider trades
5 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jun 2, 2026 | TANG KEVINChief Executive Officer · O·D·10% | ▲ Buy | 206,005 | $15.28 | $3.1M | +1.6% | indirect |
| Jun 1, 2026 | TANG KEVINChief Executive Officer · O·D·10% | ▲ Buy | 99 | $15.34 | $2K | — | indirect |
| Jun 1, 2026 | TANG KEVINChief Executive Officer · O·D·10% | ▲ Buy | 343,521 | $15.28 | $5.2M | +2.7% | indirect |
| May 29, 2026 | TANG KEVINChief Executive Officer · O·D·10% | ▲ Buy | 262,682 | $15.31 | $4.0M | +2.1% | indirect |
| May 29, 2026 | TANG KEVINChief Executive Officer · O·D·10% | ▲ Buy | 2,299 | $15.35 | $35K | — | indirect |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $AUPH feed.